

1 DNA-terminus-dependent transcription by T7 RNA polymerase and

2 its C-helix mutants

3 Bingbing Yu^a, Yifan Chen^a, Yan Yan and Bin Zhu^{*}

4 Key Laboratory of Molecular Biophysics, the Ministry of Education, College of Life Science and
5 Technology, Huazhong University of Science and Technology, Wuhan, Hubei 430074, China;

⁶ ^aThese authors contribute equally to this work;

⁷ *To whom correspondence should be addressed Email: bin_zhu@hust.edu.cn

9 ABSTRACT

10 The remarkable success of mRNA-based vaccines has underscored their potential as a
11 novel biotechnology platform for vaccine development and therapeutic protein delivery.
12 However, the single-subunit RNA polymerase from bacteriophage T7 widely used for
13 *in vitro* transcription is well known to generate double-stranded RNA (dsRNA)
14 byproducts that strongly stimulate the mammalian innate immune response. The
15 dsRNA was reported to be originated from self-templated RNA extension or promoter-
16 independent transcription. Here, we identified that the primary source of the full-length
17 dsRNA during *in vitro* transcription is the DNA-terminus-initiated transcription by T7
18 RNA polymerase. Guanosines or cytosines at the end of DNA templates enhance the
19 DNA-terminus-initiated transcription. Moreover, we found that aromatic residues
20 located at position 47 in the C-helix interfere with the binding of T7 RNA polymerase
21 to DNA termini, leading to a significant reduction in the production of full-length
22 dsRNA. As a result, the mRNA synthesized using the T7 RNA polymerase G47W
23 mutant exhibits higher expression efficiency and lower immunogenicity compared to
24 the mRNA produced using the wild-type T7 RNA polymerase.

26 INTRODUCTION

27 The extraordinary success of mRNA-based vaccines against the COVID-19 pandemic
28 highlighted the potential of mRNA-based biotechnology for vaccine development and
29 therapeutic protein delivery (1-4). As an emerging class of medicines, mRNA-based

1 therapeutics are considered safer, more efficient, and more economical compared to
2 DNA-based therapeutics and conventional protein/peptide drugs (5,6). The only
3 available method to produce large amounts of designed mRNA is the *in vitro*
4 transcription (IVT) carried out by single-subunit RNA polymerases (ssRNAPs).
5 However, the most popular ssRNAP, from bacteriophage T7, is known to generate
6 undesired double-stranded RNA (dsRNA) byproducts that can stimulate the
7 mammalian innate immune system (7,8). The dsRNA byproducts of T7 RNAP are
8 mainly generated by self-template extension (9-13) or promoter-independent
9 transcription (14,15). For therapeutic applications that require as much as a 1000-fold
10 higher level of protein than vaccines to reach the therapeutic threshold, it is necessary
11 to reduce the immuno-stimulatory effect of the dsRNA to a safe level (1-5).

12 Previous studies demonstrated that incorporation of modified nucleotides such as
13 N1-methylpseudouridine ($me^1\psi$) could reduce the immunogenicity of *in vitro*
14 transcribed RNA (16-20). Certain modified nucleotides inhibit the generation of dsRNA
15 byproducts in T7-RNAP-based IVT (15,21). Other efforts to reduce the production of
16 dsRNA byproducts include applying high-salt transcription conditions with tight-
17 binding promoter variants (22), co-tethering promoter DNA and T7 RNAP on magnetic
18 beads (23), adding competing 3'-capture DNA (24) or chaotropic agents (2), and
19 lowering the Mg^{2+} concentration (15,21). In addition, post-transcriptional purification
20 techniques such as reverse-phase high-pressure liquid chromatography (HPLC) (18,25)
21 or cellulose chromatography (26) can also reduce dsRNA contaminants. Nevertheless,
22 the above methods would increase manufacturing costs, decrease yield, and/or
23 introduce new contaminants.

24 Recent studies have focused on ssRNAP, the core component of IVT, to reduce
25 dsRNA production. Lu et al. and Xia et al. reported that two novel ssRNAPs, from
26 *Klebsiella* phage KP34 (27) and *Pseudomonas* phage VSW-3 (28,29), respectively,
27 produced minimal self-templated dsRNA. Wu et al. reported that thermostable T7
28 RNAP mutants are able to synthesize functional mRNA with reduced immunogenicity
29 at a high temperature (50°C) (30). Wu et al. reported that a single mutation S43Y

1 attenuated RNA-dependent RNAP activity of T7 RNAP by weakening the RNA
2 rebinding (31). Dousis et al. reported that an engineered T7 RNAP containing mutations
3 G47A and 884G increased the 3' homogeneity of transcribed RNA from 6–12% to more
4 than 90% (32).

5 dsRNA contaminants in IVT products include short dsRNA and long dsRNA similar
6 in length to the desired ssRNA transcript (referred to as the full-length dsRNA); the
7 latter is more significant in triggering an immune response since it mimics the viral
8 genome. In this work, we focused on the full-length dsRNA and solutions to reduce its
9 production. We demonstrated that the full-length dsRNA is derived from the promoter-
10 independent DNA-terminus-initiated transcription of T7 RNAP. We also identified the
11 initiation sites of the promoter-independent transcription of T7 RNAP and found that
12 the guanosines and cytosines at the end of DNA templates enhance the promoter-
13 independent transcription. We carried out a tyrosine screen on residues 42–48 in the C-
14 helix of T7 RNAP, which is important for association with the DNA template (31-34),
15 and found that substitutions of G47 with aromatic amino acids attenuate the promoter-
16 independent transcription significantly by weakening the non-specific binding of T7
17 RNAP to DNA termini. Among these T7 RNAP mutants, G47W was found to produce
18 the least full-length dsRNA.

19

20 MATERIALS AND METHODS

21 Protein expression and purification

22 DNA fragments encoding T7 RNAP variants were inserted into the pQE82L vector and
23 DNA fragments encoding WT SP6 RNAP were inserted into the pET28b vector with
24 N-terminal His-tags. The vectors were transformed into *Escherichia. coli* BL21 (DE3),
25 and cells were cultured in 1 L LB medium containing 100 mg/ml ampicillin (for T7-
26 RNAP-pQE82L vector) or 50 mg/ml kanamycin (for SP6-RNAP-pET28b vector) at
27 37°C until the OD600 reached 1.2. Overexpression of RNAPs was induced by addition
28 of 0.5 mM IPTG and continuous incubation at 16°C for 16 h. The cells were collected,
29 resuspended in buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl), and lysed by

1 ultrasonication. Then, the RNAPs were purified with Ni-NTA-agarose columns
2 (Qiagen) in buffer (50 mM Tris-HCl, pH 7.5, 300 mM NaCl) and a HiTrap Q HP
3 column (cytiva) as per the manufacturer's protocol. Finally, the concentrated proteins
4 were dialyzed two times against dialysis buffer (100 mM NaCl, 50 mM Tris-HCl, pH
5 7.5, 1 mM DTT, 0.1 mM EDTA, 50% glycerol, 0.1% Triton X-100). VSW-3, KP34,
6 and Syn5 RNAP were purified as described previously (27-29,35,36).

7 **Transcription assays**

8 Sequences of the DNA templates and primers are shown in Table S1. All the DNA
9 templates were prepared by PCR (Takara) unless otherwise noted. IVT reactions by T7,
10 KP34 (27), SP6 (37), or VSW-3 RNAP (28) contained 40 mM Tris-HCl, pH 8.0, 15
11 mM MgCl₂, 2 mM spermidine, 5 mM DTT, 0.2 μM inorganic pyrophosphatase, 1.5
12 U/μl RNase inhibitor, 4 mM each of ATP, CTP, GTP, and UTP, 30 ng/μl DNA templates,
13 and 0.2 μM RNAP. The reaction mixtures were incubated at 37°C for 2 h (unless
14 otherwise indicated) or at 25°C for 16 h (only for VSW-3 RNAP). IVT reactions by
15 Syn5 RNAP containing 40 mM Tris-HCl, pH 8.0, 15 mM MgCl₂, 2 mM spermidine, 5
16 mM DTT, 0.2 μM inorganic pyrophosphatase, 1.5 U/μl RNase inhibitor, 4 mM each of
17 ATP, CTP, GTP, and UTP, 30 ng/μl DNA templates, and 2 μM RNAP were incubated
18 at 30°C for 4 h (35). After incubation, 1 unit of DNase I was added to the reaction
19 mixtures to remove DNA templates. In some assays, the DNase I treatment was omitted
20 to show the DNA templates along with the transcripts. Then, the IVT products were
21 purified with Monarch RNA purification kits (New England Biolabs, NEB), and the
22 purified RNA was quantified using a nanophotometer (IMPLEN). To show the abortive
23 products during the transition from transcription initiation to elongation, 0.32 mM
24 fluorescently labeled dinucleotide 6-FAM-GG was added into the IVT reactions. The
25 gels were imaged and analyzed using a ChemiScope 6000 Imaging System (CLINX).

26 **RNase III/RNase I_f digestion**

27 For RNase digestion, 600 ng GFP RNA was incubated with 1, 2, 4, or 8 μl RNase III
28 (1:1000 diluted, New England Biolabs) or RNase I_f (1:100 diluted, New England
29 Biolabs) in buffer 3 (100 mM NaCl, 50 mM Tris-HCl, pH 7.9, 10 mM MgCl₂, and 1

1 mM DTT, New England Biolabs) or in 50 mM NaCl, 50 mM Tris-HCl, pH 7.5, 20 mM
2 MnCl₂, and 1 mM DTT at 37°C for 30 min. Reactions were terminated by heat
3 inactivation at 85°C for 5 min.

4 **Native gel electrophoresis**

5 To visually distinguish ssRNA and dsRNA, IVT transcripts were analyzed by 6% TBE
6 polyacrylamide gel electrophoresis and stained by acridine orange (AO) (Sigma
7 Aldrich). Fluorescence gel images were obtained by a ChemiScope 6000 Imaging
8 System (CLINX). For ssRNA-specific image, the 473-nm filter was used for excitation
9 and the 792-nm filter was used for emission. For dsRNA-specific image, the 532-nm
10 filter was used for excitation and the 554-nm filter was used for emission. The
11 fluorescence images were superimposed.

12 **Dot blot**

13 Various concentrations of IVT transcripts were dropped onto an Immobilon TM-Ny+
14 Membrane (Millipore), which was dried, blocked with 5% non-fat dry milk in TBS-T
15 buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, and 0.05% Tween-20), and incubated
16 with dsRNA-specific J2 mAb (SCICONS) for 30 min at 25°C. The membrane was
17 washed three times with TBS-T buffer and incubated with hydrogen peroxidase-
18 conjugated donkey anti-mouse Ig (1:2000 diluted, Jackson Immunology). After
19 washing the membrane three times, chemiluminescence detection was performed using
20 the ECL™ Enhanced Pico Light Chemiluminescence Kit (EpiZyme) and a
21 ChemiScope 6000 Imaging System (CLINX).

22 **RNA 5'RACE and 3'RACE**

23 A 200-nt RNA linker was prepared by IVT and its triphosphate group was converted to
24 a monophosphate group by RppH (New England Biolabs) for 3'RACE. Then, the GFP
25 RNA was linked to the treated linker with T4 RNA ligase 1 (New England Biolabs).
26 The obtained RNA was purified with the Monarch RNA purification kit (New England
27 Biolabs), and reverse transcription (RT) was performed with a specific primer using
28 Magicscript thermotolerant reverse transcriptase (MAGIGEN). Then, the cDNA was
29 amplified by PCR with a pair of specific primers and purified with the AxyPrep PCR

1 Cleanup kit (Axygen). The cDNA was inserted into the plasmid pUC18 and subjected
2 to Sanger sequencing (Genecreate). For 5'RACE, the GFP RNA was treated with RppH
3 and linked to the 200-nt RNA linker, following the same steps as those for 3'RACE. All
4 primers used are listed in Table S1.

5 **DNA binding**

6 Various dsDNA fragments (2 μ M, sequences are shown in Table S1) with or without
7 T7 promoter were incubated with various concentrations (0, 0.5, 1, and 2 μ M) of WT
8 T7 RNAP or its G47W or E45K mutant in 40 mM Tris-HCl, pH 8.0, 15 mM MgCl₂, 2
9 mM spermidine, and 5 mM DTT at 37°C for 10 min. The mixtures were mixed with 5
10 μ l RNA dye (New England Biolabs) and separated by 12% TBE PAGE. Gels were
11 stained with ethidium bromide, and images were analyzed by ImageJ and Prism.

12 **Quantitative analysis**

13 The gray value of gel bands and immuno-blot dots was quantified with ImageJ software,
14 and the diagrams were generated by Prism.

15 **mRNA synthesis**

16 First, 3.2 mM CleanCap AG (3' OMe) (Trilink) was added to the IVT reaction by T7
17 RNAP or T7 RNAP-G47W to obtain 5'-capped GFP RNA. The capped RNA was
18 purified with the Monarch RNA purification kit, and a poly(A) tail was added to the
19 capped RNA by *E. coli* poly(A) polymerase (New England Biolabs). The final GFP
20 mRNA was purified with the Monarch RNA purification kit.

21 **Cell culture and flow cytometry**

22 293T cells were cultured in 24-well plates (NEST) in Dulbecco's modified Eagle
23 medium (Gibco) supplemented with 10% fetal calf serum (Gibco), 1%
24 penicillin/streptomycin (Thermo Fisher Scientific), and 2.5 mg/ml plasmocin
25 prophylactic (Invivogen). At about 80% confluence, the cells were transfected with 500
26 ng GFP mRNA encapsulated in lipofectamine2000 (Thermo Fisher Scientific) as per
27 the manufacturer's protocol. GFP expression levels were recorded by fluorescence
28 microscopy at 4, 8, and 20 h after transfection. After 20 h, fluorescence intensity was
29 quantified by flow cytometry using SH800S (SONY).

1 **IFN- β detection**

2 293T cells were cultured in 6-well plates as described above. At about 80% confluence,
3 the cells were transfected with 2000 ng GFP mRNA encapsulated in lipofectamine2000
4 (Thermo Fisher Scientific) as per the manufacturer's protocol. After 20 h, the cells were
5 collected, lysed, and centrifuged, and the IFN- β in the supernatant was detected using
6 the Human IFN- β (Interferon Beta) ELISA Kit (Elabscience) as per the manufacturer's
7 protocol.

8

9 **RESULTS**

10 **T7 RNA polymerase produces full-length dsRNA byproducts in IVT**

11 Four common DNA templates (*gfp*, *sox7*, the *S-gene* from SARS-CoV2, and *cas9*) were
12 transcribed by T7 RNAP. The IVT products were analyzed by native agarose gel
13 electrophoresis (Figure 1A) and dot blot analysis (Figure 1B). The dot blot assay
14 detected dsRNA byproducts in all the transcripts, with the highest dsRNA content in
15 GFP transcripts (Figure 1B). Consistently, we observed an obvious band above the gel
16 band corresponding to the desired GFP ssRNA (Figure 1A). The position of the upper
17 band indicates a byproduct corresponding to the full-length GFP dsRNA. To confirm
18 the identity of this byproduct, we digested the GFP transcripts with RNase I_f and RNase
19 III, which specifically degrade ssRNA and dsRNA, respectively. Then, the RNase-
20 treated transcripts were analyzed by native agarose gel electrophoresis or PAGE,
21 followed by ethidium bromide or acridine orange dyeing, as previously reported (15).
22 The upper band was sensitive to RNase III but not to RNase I_f (Figure 1C), confirming
23 that it presents dsRNA. As expected for the full-length dsRNA, it migrated faster than
24 the single-stranded GFP RNA in the native PAGE (Figure 1D). Acridine orange staining
25 further distinguished the GFP ssRNA (orange) from the full-length dsRNA (green)
26 (Figure 1D). To reveal the mechanism of full-length dsRNA formation, we focused on
27 the GFP transcripts with the most significant full-length dsRNA content for following
28 investigations.

29

1 **T7 RNA polymerase initiates transcription from DNA terminus without promoter**

2 Previous studies reported that the large dsRNA byproducts of T7 RNAP were mainly
3 generated by self-templated RNA extension (9-13) or promoter-independent
4 transcription (15,21). To reveal the origin of the full-length dsRNA in GFP transcripts,
5 we extended the *gfp* DNA templates with 53-, 290-, or 583-bp non-coding sequences at
6 the 5' termini, upstream of the T7 promoter (Figure 2A). These extensions do not affect
7 the desired GFP ssRNA initiated from the promoter, so the size of the full-length dsRNA
8 would not change if it originated from the self-templated RNA extension as described
9 previously (9-13). However, if T7 RNAP initiates transcription at the 3'-termini of the
10 DNA template, the antisense GFP transcript would be extended following the extension
11 of the antisense DNA, and the size of the full-length dsRNA annealed by the GFP
12 transcript (initiated at the promoter) and the antisense GFP transcript (initiated at the 3'
13 DNA terminus) would also increase. As shown in Figure 2A, the gel bands
14 corresponding to the GFP ssRNA had the same mobility, despite the template 5'
15 extension. However, the gel mobilities of the upper bands corresponding to the full-
16 length dsRNA were lower following the template 5' extensions, confirming that the full-
17 length dsRNA in GFP transcripts originated from promoter-free DNA-terminus-
18 initiated transcription (Figure 2B) but not from RNA-templated self-extension. To
19 further characterize the antisense transcript, we performed 3'RACE and 5'RACE
20 analyses on the antisense RNA from the GFP DNA template with a 290-bp 5' extension.
21 The results of our 5'RACE analysis showed that most of the antisense RNA initiated
22 from the second base at the non-promoter end of the DNA template (Figure 2C).
23 3'RACE analysis showed that the 3' sequence of the antisense RNA matches the 5'
24 sequence of the antisense strand of the template DNA, confirming the run-off
25 termination of the antisense RNA (Table S2).

26 Previous studies (14,15) have demonstrated that the terminal structures of DNA
27 templates influence the production of dsRNA by T7 RNAP, with the 3' protruding DNA
28 ends leading to more dsRNA production. The result that the production of full-length
29 dsRNA (Figure 1A and B) varied among various DNA templates (all produced by PCR

1 with blunt ends) indicates that the terminal sequences of DNA templates affect the
2 DNA-terminus-initiated transcription by T7 RNAP. To clarify such influence, we
3 prepared eight blunt-ended DNA templates with various 4-bp terminal sequences by
4 PCR and examined their transcripts generated by T7 RNAP (Figure 2D). We calculated
5 the proportion of dsRNA and found that DNA templates with four consecutive Gs at
6 the ends yielded the most full-length dsRNA (Figure 2E). In contrast, DNA templates
7 with four As or Ts at the ends yielded the least dsRNA. These results are consistent with
8 a previous report showing that adding poly(dA) to the 3' end of DNA templates reduces
9 dsRNA generation in T7 RNAP IVT (30).

10 We further tested the effect of single variations in the 4-bp (5'-TTTT-3') template
11 terminal sequence on the production of full-length dsRNA. Each of the four terminal
12 Ts was replaced by G, C, or A. The IVT products were analyzed by agarose gel
13 electrophoresis (Figure 2F) and dot blot analysis (Figure 2G). Then we quantified the
14 dsRNA from these templates based on Figure 2G and compared them to that from the
15 original template (Figure 2H). Results showed that the last two bases have the most
16 significant impact on the generation of full-length dsRNA; a single guanosine or
17 cytidine in the terminal 2-nt region increases the yield of full-length dsRNA.

18

19 **DNA-terminus-dependent transcription is not common for bacteriophage**
20 **ssRNAPs**

21 Bacteriophages encoding ssRNAPs belong to the *Autographivirinae*, a subfamily of
22 the *Podoviridae*, which were classified into four distinct clusters corresponding to
23 phiKMV-, P60-, SP6-, and T7-like viruses (38) (Figure 3A). We have characterized
24 Syn5 (36) and KP34 (27) RNAP as the representative ssRNAPs of the P60-like and
25 phiKMV-like bacteriophages distantly related to T7, respectively. Bacteriophage VSW-
26 3, which encodes another recently characterized ssRNAP (28), most likely also belongs
27 to the cluster of phiKMV-like viruses based on its genomic organization (Figure 3B).
28 We aimed to determine whether these distantly related ssRNAPs also catalyze the
29 DNA-terminus-dependent transcription and produce the full-length dsRNA. With DNA

1 templates harboring the same GFP coding sequence, we compared the production of
2 the full-length dsRNA by these ssRNAPs to that by T7 and SP6 RNAP (37).
3 Interestingly, among the five ssRNAPs investigated, KP34 and VSW-3 RNAP do not
4 produce detectable full-length dsRNA (Figure 3C and D), indicating the ssRNAPs from
5 phiKMV-like viruses might not initiate transcription from DNA termini. Thus, DNA-
6 terminus-initiated, promoter-independent transcription is not a common feature for
7 bacteriophage ssRNAPs.

8

9 **T7 RNAP mutants with low full-length dsRNA production**

10 Previous efforts (2,17-32) have been made to eliminate the dsRNA byproducts in
11 IVT, which is the major source of immunogenicity for mRNA therapeutics. However,
12 these works have barely focused on the dsRNA generated by promoter-independent
13 antisense transcription. The fact that KP34 and VSW-3 RNAP do not initiate
14 transcription from DNA termini encouraged us to engineer T7 RNAP to reduce its
15 DNA-terminus-dependent transcription. Previous studies (31-34) suggested that the C-
16 helix (residues 28–71) of T7 RNAP is important for the association between the DNA
17 template and RNAP. The intact C-helix is formed during the transition from
18 transcription initiation to elongation (33), with drastic conformational changes
19 occurring at the two hinge residues, Ser43 and Gly47 (Figure 4A). Dousis et al. reported
20 that alanine substitution at position 47 of T7 RNAP is the most advantageous for the
21 formation of the C-helix, thus reducing the production of self-extended dsRNA to the
22 highest extent (32). Our previous work applying directed evolution revealed that a
23 tyrosine substitution at position 43 of T7 RNAP causes the most significant reduction
24 of the terminal self-extended dsRNA (31). Hence, we performed a “tyrosine screen” for
25 residues 42–48 by substituting each of the residues with tyrosine and examined the IVT
26 products by these T7 RNAP mutants on GFP templates (Figure 4B). Interestingly,
27 tyrosine substitutions at these positions showed various effects on the production of
28 full-length dsRNA: E42Y and E45Y mutations increased the production of full-length
29 dsRNA; S43Y slightly reduced the production of full-length dsRNA; while G47Y

1 significantly reduced the production of full-length dsRNA (Figure 4C). To further
2 confirm whether aromatic residues at position 47 cause the observed effect, we mutated
3 G47 to Tyr, Trp, Phe, His, and Ala and analyzed their effects on the production of full-
4 length dsRNA (Figure 4D and E). All these mutations reduced the production of full-
5 length dsRNA by T7 RNAP, with aromatic residues showing the strongest effects
6 (Figure 4F). Among them, the G47W mutant, with the largest residue at position 47,
7 produced the least full-length dsRNA. The amount of full-length dsRNA in the GFP
8 transcripts produced by the G47W mutant was reduced 9-fold compared with that
9 produced by wild-type T7 RNAP (Figure 4F).

10

11 **G47W reduces the promoter-independent transcription by weakening the binding**
12 **of T7 RNAP to DNA terminus**

13 In contrast to G47Y, mutations E42Y and E45Y increased the production of full-
14 length dsRNA (Figure 4C). To investigate the influence of the negative charge of these
15 C-helix residues on the DNA-terminus-dependent transcription by T7 RNAP, we
16 replaced the three negatively charged glutamic acids in the C-helix with positively
17 charged lysine residues. Both gel electrophoresis (Figure 5A) and dot blot analyses
18 (Figure 5B and C) showed significant increases in the production of full-length dsRNA
19 in the IVT of GFP RNA by E42K, E45K, and E48K mutants compared to that by the
20 wild-type T7 RNAP. The most significant increase was observed for the E45K mutant
21 (Figure 5C). To elucidate the mechanism by which G47W and E45K mutations affect
22 the DNA-terminus-dependent transcription by T7 RNAP, we designed a 40-bp DNA
23 sequence without T7 promoter at the 5' end but with three consecutive Gs at the 3'-
24 terminus and investigated the binding of such DNA template by the wild-type T7 RNAP
25 and its G47W and E45K mutants. Wild-type, G47W, or E45K T7 RNAP was incubated
26 with the promoter-less DNA, and the binding of the enzymes to the DNA was analyzed
27 by 12% native PAGE (Figure 5D and E). The EMSA results showed weak but specific
28 slowly moving gel bands for wild-type T7 RNAP and the E45K mutant, indicating
29 promoter-independent binding to the DNA terminus. However, such binding was not

1 observed for the G47W mutant, consistent with its low dsRNA production. These
2 results further support the notion that the full-length dsRNA originates from the
3 promoter-independent transcription from DNA terminus.

4 We also investigated the effect of G47W or E45K mutation on the normal functions
5 of T7 RNAP. First, the binding of wild-type and mutant RNAPs to the DNA containing
6 a T7 promoter was evaluated. Inconsistent with the binding to DNA terminus, the
7 binding to the T7 promoter was not significantly affected by the G47W mutation, while
8 unexpectedly, the E45K mutation decreased the binding of T7 RNAP to its promoter
9 (Figure 5F and G). These results suggest different modes of promoter or DNA terminus
10 binding by T7 RNAP.

11 Moreover, as the intact C-helix is formed during the transition from transcription
12 initiation to elongation (33), we also investigated the influence of G47W or E45K
13 mutation on this step. T7 RNAP is known to initiate transcription efficiently with
14 dinucleotides matching the initial RNA sequences (39,40), so we designed a 53-bp
15 template with a T7 promoter, followed by three consecutive Gs, and added the
16 fluorescently labeled dinucleotide 6-FAM-GG into the reactions to initiate the IVT by
17 wild-type T7 RNAP or its G47W or E45K mutant. At 10, 20, 40, and 80 min after
18 initiation of the reactions, 0.5 μ l of every sample was taken and analyzed by 20%
19 denaturing PAGE. Then, fluorescence gel image of RNA transcripts was obtained using
20 the 492-nm and 517-nm filters for excitation and emission, respectively, and the image
21 was converted into black/white (Figure 5H). We quantified the yield of run-off ssRNA
22 and the abortive RNA products. The result demonstrated that the G47W mutant initiates
23 transcription more efficiently with the dinucleotide GG compared to wild-type T7
24 RNAP to produce more run-off and abortive RNA (Figure 5I). However, the ratio
25 between the abortive and run-off products was not significantly changed by the G47W
26 mutation (Figure 5H and I), indicating that the transition from transcription initiation to
27 elongation was not affected. In contrast, the E45K mutation severely reduced the
28 initiation and the yield in IVT (Figure 5H and I), consistent with its effect on promoter
29 binding.

1

2 **T7 RNAP-G47W is an ideal engineered RNA polymerase for mRNA production**

3 To evaluate the advantages of T7 RNAP-G47W in mRNA production, we compared
4 wild-type T7 RNAP and T7 RNAP-G47W in the IVT production of GFP, Cas9, and S-
5 gene RNA. Another mutant of T7 RNAP, G47A+884G, which was recently reported to
6 significantly reduce the self-templated dsRNA (32), was also included in the
7 comparison. For both the G47W and G47A+884G mutants, the gel bands corresponding
8 to the full-length dsRNA in the GFP IVT products were not observable (Figure 6A),
9 indicating that DNA-terminus-initiated transcription by the G47A+884G mutant is also
10 reduced compared to that by the wild-type T7 RNAP. The IVT yield of GFP RNA, with
11 a relatively short length (873 nt), was similar for wild-type T7 RNAP and both mutants
12 (Figure 6A and B). However, when synthesizing large RNA molecules like Cas9 (4314
13 nt) and S-gene (3975 nt), the IVT yield of the G47W mutant was slightly lower than
14 that of wild-type T7 RNAP, while the IVT yield of the G47A+884G mutant was
15 obviously reduced (Figure 6C–F). In addition, the G47A+884G mutant produced more
16 terminated products compared to the wild-type and G47W T7 RNAP (Figure 6C and E,
17 indicated by purple arrows).

18 To compare the expression efficiency of mRNA produced by wild-type T7 RNAP
19 and the G47W mutant, we transfected 293T cells with GFP mRNA synthesized by either
20 enzyme, and their expression levels were recorded by fluorescence microscopy at 4, 16,
21 and 20 h after transfection (Figure 6G). After 20 h, we quantified their fluorescence
22 intensity by flow cytometry (Figure 6H). As expected, mRNA transcribed by the G47W
23 mutant showed much higher expression levels than that transcribed by wild-type T7
24 RNAP. We also determined the concentration of IFN- β in 293T cells at 20 h after
25 transfection by ELISA and found that almost no IFN- β response was induced in the
26 cells transfected with GFP mRNA produced by the G47W mutant compared to the
27 negative control (Figure 6I). However, the mRNA produced by wild-type T7 RNAP
28 elicited a strong IFN- β response. These results are consistent with the low production
29 of full-length dsRNA by the T7 RNAP-G47W mutant and demonstrate its value as an

1 advantageous enzymatic tool for mRNA medicine and vaccine.

2

3 **DISCUSSION**

4 It is well known that mRNA transcribed by T7 RNAP can stimulate the mammalian
5 innate immune system and that it is necessary to reduce the immuno-stimulatory effect
6 of the dsRNA to fit therapeutic applications. Previous studies (9-11,13) focused on the
7 dsRNA generated by self-template extension. Recently, Ma et al. reported that wild-
8 type T7 RNA polymerase can initiate transcription from the end of the DNA in a
9 promoter-independent manner to generate full-length dsRNA and that this transcription
10 could be suppressed by low concentrations of Mg²⁺ (15). Yet, the mechanisms
11 underlying such non-conventional transcription remain elusive.

12 In the present study, we further analyzed the promoter-independent transcription by
13 T7 RNAP and revealed more details about the process. We demonstrated that the
14 production of antisense RNA is mostly initiated from the penultimate position of the
15 DNA terminus and that the presence of guanosine or cytidine in the 2-nt terminal region
16 of the DNA template strengthens the promoter-independent transcription by T7 RNAP
17 significantly. Therefore, adding poly(A) to the end of DNA templates is an effective
18 way to reduce the amounts of full-length dsRNA in mRNA production.

19 Moreover, we tested the full-length dsRNA production by various ssRNAPs and
20 found that DNA-terminus-dependent transcription is not common for bacteriophage
21 ssRNAPs. Although T7, SP6, and Syn5 RNAP as representative ssRNAPs all produce
22 significant amounts of full-length dsRNA in IVT, the products of KP34 and VSW-3
23 RNAP from phiKMV-like viruses contain non-detectable dsRNA generated by
24 promoter-independent transcription.

25 Previous studies proved that mutations S43Y and G47A in T7 RNAP were able to
26 attenuate the self-template extension (31,32). In the structure of the elongation complex
27 of T7 RNAP, this region is in close proximity to the DNA template (33,34) (Figure 4A).
28 We replaced residues 42–48 of T7 RNAP with various amino acids, and the results
29 showed that substitutions of G47 with aromatic amino acids most significantly reduce

1 the dsRNA generated from promoter-independent transcription. In contrast,
2 substitutions of negatively charged E42, E45, or E48 with lysine enhanced the
3 promoter-independent transcription. Moreover, we demonstrated that compared to
4 wild-type T7 RNAP, the G47W mutant showed no detectable binding to DNA terminus.
5 These results indicate that aromatic amino acids at position 47 hinder the binding of T7
6 RNAP to the DNA terminus, most likely due to spatial steric hindrance. In summary,
7 our results demonstrate the importance of residues 42–48 of T7 RNAP for the
8 interaction with DNA; these residues may serve as potential targets for further
9 engineering.

10 In summary, we generated a superior T7 RNAP mutant, G47W, with minimal dsRNA
11 production while maintaining high yield, especially in the production of large mRNA
12 molecules. The mRNA synthesized by T7 RNAP-G47W shows high expression
13 efficiency and low immunogenicity, indicating that T7 RNAP-G47W is suitable for
14 therapeutic applications.

15

16 **SUPPLEMENTARY DATA**

17 Supplementary data are available at NAR online.

18

19 **ACKNOWLEDGEMENT**

20 We thank all lab members for helpful discussion.

21

22 **FUNDING**

23 This project is funded by the National Natural Science Foundation of China (grant
24 32150009 to B.Z.). Funding for open access charge: National Natural Science
25 Foundation of China.

26

27 **CONFLICT OF INTEREST**

28 The authors declared that they have no conflicts of interest to this work.

29

1 **AUTHOR CONTRIBUTION STATEMENT**

2 B.Z. conceived the project. B.B.Y. and B.Z. designed the experiments. B.B.Y., Y.F.C.
3 and carried out the experiments. B.B.Y., Y.F.C., Y.Y. and B.Z. analyzed the data. B.B.Y.
4 and B.Z. wrote the manuscript. All authors discussed the results and contributed to the
5 final manuscript.

6

7 **REFERENCES**

- 8 1. Rohner, E., Yang, R., Foo, K.S., Goedel, A. and Chien, K.R. (2022) Unlocking the
9 promise of mRNA therapeutics. *Nature biotechnology*, **40**, 1586-1600.
- 10 2. Piao, X., Yadav, V., Wang, E., Chang, W., Tau, L., Lindenmuth, B.E. and Wang, S.X.
11 (2022) Double-stranded RNA reduction by chaotropic agents during in vitro
12 transcription of messenger RNA. *Molecular therapy. Nucleic acids*, **29**, 618-624.
- 13 3. Baden, L.R., El Sahly, H.M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D.,
14 Spector, S.A., Roush, N., Creech, C.B. *et al.* (2021) Efficacy and Safety of the
15 mRNA-1273 SARS-CoV-2 Vaccine. *The New England journal of medicine*, **384**, 403-
16 416.
- 17 4. Polack, F.P., Thomas, S.J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez,
18 J.L., Perez Marc, G., Moreira, E.D., Zerbini, C. *et al.* (2020) Safety and Efficacy of the
19 BNT162b2 mRNA Covid-19 Vaccine. *The New England journal of medicine*, **383**,
20 2603-2615.
- 21 5. Pardi, N., Hogan, M.J., Porter, F.W. and Weissman, D. (2018) mRNA vaccines - a new
22 era in vaccinology. *Nature reviews. Drug discovery*, **17**, 261-279.
- 23 6. Qin, S., Tang, X., Chen, Y., Chen, K., Fan, N., Xiao, W., Zheng, Q., Li, G., Teng, Y.,
24 Wu, M. *et al.* (2022) mRNA-based therapeutics: powerful and versatile tools to combat
25 diseases. *Signal transduction and targeted therapy*, **7**, 166.
- 26 7. Peisley, Aly, Myung, Hyun, Jo, Lin, Cecilie, Bin, Wu and Orme-Johnson. (2012)
27 Kinetic mechanism for viral dsRNA length discrimination by MDA5 filaments.
28 *Proceedings of the National Academy of Sciences of the United States of America*, **109**,
29 3340-3349.

1 8. Pichlmair, A., Schulz, O., Tan, C.P., Nslund, T.I., Liljestrm, P., Weber, F. and Sousa, C.R.E. (2006) Rig-I-mediated antiviral responses to single-stranded rna bearing 5' phosphates. *Science*, **314**, 997-1001.

2 9. Triana-Alonso, F.J., Dabrowski, M., Wadzack, J. and Nierhaus, K.H. (1995) Self-coded 3'-extension of run-off transcripts produces aberrant products during in vitro transcription with T7 RNA polymerase. *The Journal of biological chemistry*, **270**, 6298-6307.

3 10. Uhlenbeck, C.O.C. (1994) RNA template-directed RNA synthesis by T7 RNA polymerase. *Proceedings of the National Academy of Sciences*, **91**, 6972-6976.

4 11. Biebricher, C.K. and Luce, R. (1996) Template-free generation of RNA species that replicate with bacteriophage T7 RNA polymerase. *The EMBO Journal*, **15**, 3458-3465.

5 12. Jain, N., Blauch, L.R., Szymanski, M.R., Das, R., Tang, S.K.Y., Yin, Y.W. and Fire, A.Z. (2020) Transcription polymerase-catalyzed emergence of novel RNA replicons. *Science*, **368**.

6 13. Gholamalipour, Y., Karunananayake Mudiyanselage, A. and Martin, C.T. (2018) 3' end additions by T7 RNA polymerase are RNA self-templated, distributive and diverse in character-RNA-Seq analyses. *Nucleic acids research*, **46**, 9253-9263.

7 14. Schenborn, E.T. and Mierendorf, R.C. (1985) A novel transcription property of SP6 and T7 RNA polymerases: dependence on template structure. *Nucleic acids research*, **13**, 6223-6236.

8 15. Mu, X., Greenwald, E., Ahmad, S. and Hur, S. (2018) An origin of the immunogenicity of in vitro transcribed RNA. *Nucleic acids research*, **46**, 5239-5249.

9 16. Kariko, K., Buckstein, M., Ni, H. and Weissman, D. (2005) Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. *Immunity*, **23**, 165-175.

10 17. Anderson, B.R., Muramatsu, H., Nallagatla, S.R., Bevilacqua, P.C., Sansing, L.H., Weissman, D. and Kariko, K. (2010) Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation. *Nucleic acids research*, **38**, 5884-5892.

1 18. Sriram, V., Azizian, K.T., Ashiqul, H.A.K.M., Henderson, J.M., Ayal, H., Sabrina, S.,
2 Antony, J.S., Hogrefe, R.I., Kormann, M.S.D. and Porteus, M.H. (2018) Uridine
3 Depletion and Chemical Modification Increase Cas9 mRNA Activity and Reduce
4 Immunogenicity Without HPLC Purification. *Molecular Therapy - Nucleic Acids*, **12**,
5 530-542.

6 19. Nelson, J., Sorensen, E.W., Mintri, S., Rabideau, A.E. and Joyal, J.L. (2020) Impact of
7 mRNA chemistry and manufacturing process on innate immune activation. *Science
8 Advances*, **6**, eaaz6893.

9 20. Moradian, H., Roch, T., Anthofer, L., Lendlein, A. and Gossen, M. (2022) Chemical
10 modification of uridine modulates mRNA-mediated proinflammatory and antiviral
11 response in primary human macrophages. *Molecular therapy. Nucleic acids*, **27**, 854-
12 869.

13 21. Mu, X. and Hur, S. (2021) Immunogenicity of In Vitro-Transcribed RNA. *Accounts of
14 chemical research*, **54**, 4012-4023.

15 22. MalagodaPathiranage, K., Cavac, E., Chen, T.H., Roy, B. and Martin, C.T. (2023)
16 High-salt transcription from enzymatically gapped promoters nets higher yields and
17 purity of transcribed RNAs. *Nucleic acids research*, **51**, e36.

18 23. Cavac, E., Ramirez-Tapia, L.E. and Martin, C.T. (2021) High-salt transcription of DNA
19 cotethered with T7 RNA polymerase to beads generates increased yields of highly pure
20 RNA. *The Journal of biological chemistry*, **297**, 100999.

21 24. Gholamalipour, Y., Johnson, W.C. and Martin, C.T. (2019) Efficient inhibition of RNA
22 self-primed extension by addition of competing 3'-capture DNA-improved RNA
23 synthesis by T7 RNA polymerase. *Nucleic acids research*, **47**, e118.

24 25. Kariko, K., Muramatsu, H., Ludwig, J. and Weissman, D. (2011) Generating the
25 optimal mRNA for therapy: HPLC purification eliminates immune activation and
26 improves translation of nucleoside-modified, protein-encoding mRNA. *Nucleic acids
27 research*, **39**, e142.

28 26. Bayersdorfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U. and
29 Kariko, K. (2019) A Facile Method for the Removal of dsRNA Contaminant from In

1 Vitro-Transcribed mRNA. *Molecular therapy. Nucleic acids*, **15**, 26-35.

2 27. Lu, X., Wu, H., Xia, H., Huang, F., Yan, Y., Yu, B., Cheng, R., Drulis-Kawa, Z. and

3 Zhu, B. (2019) Klebsiella Phage KP34 RNA Polymerase and Its Use in RNA Synthesis.

4 *Frontiers in microbiology*, **10**, 2487.

5 28. Xia, H., Yu, B., Jiang, Y., Cheng, R., Lu, X., Wu, H. and Zhu, B. (2022) Psychrophilic

6 phage VSW-3 RNA polymerase reduces both terminal and full-length dsRNA

7 byproducts in in vitro transcription. *RNA biology*, **19**, 1130-1142.

8 29. Wang, G., Cheng, R., Chen, Q., Xu, Y., Yu, B., Zhu, B., Yin, H. and Xia, H. (2022)

9 mRNA produced by VSW-3 RNAP has high-level translation efficiency with low

10 inflammatory stimulation. *Cell insight*, **1**, 100056.

11 30. Wu, M.Z.A., HaruichiTzertzinis, GeorgeRoy, Bijoyita. (2020) Synthesis of low

12 immunogenicity RNA with high-temperature in vitro transcription. *RNA*, **26**, 345-360.

13 31. Wu, H., Wei, T., Yu, B., Cheng, R., Huang, F., Lu, X., Yan, Y., Wang, X., Liu, C. and

14 Zhu, B. (2021) A single mutation attenuates both the transcription termination and

15 RNA-dependent RNA polymerase activity of T7 RNA polymerase. *RNA biology*, **18**,

16 451-466.

17 32. Dousis, A., Ravichandran, K., Hobert, E.M., Moore, M.J. and Rabideau, A.E. (2023)

18 An engineered T7 RNA polymerase that produces mRNA free of immunostimulatory

19 byproducts. *Nature biotechnology*, **41**, 560-568.

20 33. Durniak, K.J., Bailey, S. and Steitz, T.A. (2008) The structure of a transcribing T7 RNA

21 polymerase in transition from initiation to elongation. *Science*, **322**, 553-557.

22 34. Bandwar, R.P., Ma, N., Emanuel, S.A., Anikin, M., Vassylyev, D.G., Patel, S.S. and

23 McAllister, W.T. (2007) The transition to an elongation complex by T7 RNA

24 polymerase is a multistep process. *The Journal of biological chemistry*, **282**, 22879-

25 22886.

26 35. Zhu, B., Tabor, S. and Richardson, C.C. (2014) Syn5 RNA polymerase synthesizes

27 precise run-off RNA products. *Nucleic acids research*, **42**, e33.

28 36. Zhu, B., Tabor, S., Raytcheva, D.A., Hernandez, A., King, J.A. and Richardson, C.C.

29 (2013) The RNA polymerase of marine cyanophage Syn5. *The Journal of biological*

1 *chemistry*, **288**, 3545-3552.

2 37. Butler, E.T. and Chamberlin, M.J. (1982) Bacteriophage SP6-specific RNA polymerase.

3 I. Isolation and characterization of the enzyme. *Journal of Biological Chemistry*, **257**,

4 5772-5778.

5 38. Drulis-Kawa, Z., Mackiewicz, P., Kęsik-Szeloch, A., Maciaszczyk-Dziubinska, E.,

6 Weber-Dąbrowska, B., Dorotkiewicz-Jach, A., Augustyniak, D., Majkowska-Skrobek,

7 G., Bocer, T., Empel, J. *et al.* (2011) Isolation and characterisation of KP34—a novel

8 φKMV-like bacteriophage for *Klebsiella pneumoniae*. *Applied Microbiology and*

9 *Biotechnology*, **90**, 1333-1345.

10 39. Kuzmine, I., Gottlieb, P.A. and Martin, C.T. (2003) Binding of the priming nucleotide

11 in the initiation of transcription by T7 RNA polymerase. *The Journal of biological*

12 *chemistry*, **278**, 2819-2823.

13 40. Depaix, A., Grudzien-Nogalska, E., Fedorczyk, B., Kiledjian, M., Jemielity, J. and

14 Kowalska, J. (2022) Preparation of RNAs with non-canonical 5' ends using novel di-

15 and trinucleotide reagents for co-transcriptional capping. *Frontiers in molecular*

16 *biosciences*, **9**, 854170.

17

18

1 **Figure legends**

2 **Figure 1.** Full-length dsRNA in the IVT products of T7 RNAP. **(A)** 1.5% agarose gel
3 electrophoresis analysis and **(B)** dot blot analysis of four genes transcribed by T7 RNAP.
4 **(C)** 1.5% agarose gel electrophoresis analysis of GFP transcripts treated with RNase I_f
5 (1/40, 1/20, 1/10, and 1/5 units/μl) and RNase III (1/10,000, 1/5000, 1/2500, and 1/1250
6 units/μl). **(D)** 6% native PAGE analysis of GFP transcripts treated with RNases as in
7 **(C)**. The gel bands were visualized by acridine orange staining. Gel bands
8 corresponding to ssRNA, dsRNA, and terminated RNA are indicated by green, orange,
9 and purple arrows, respectively.

10

11 **Figure 2.** DNA-terminus-initiated transcription by T7 RNAP. **(A)** 1.5% agarose gel
12 electrophoresis analysis of the IVT reactions by T7 RNAP on DNA templates with 5'
13 extensions. The non-coding sequences upstream of the T7 promoter of templates T1,
14 T2, and T3 were 53, 290, and 583 bp in size, respectively. T indicates the DNA
15 templates, and R indicates the transcripts. **(B)** Schematic showing the formation of full-
16 length dsRNA in IVT. **(C)** 5'RACE results of antisense RNA. Corresponding positions
17 of listed DNA and RNA sequences are indicated in the dashed red boxes in **(B)**. **(D)**
18 Agarose gel electrophoresis analysis of the IVT products of T7 RNAP on DNA
19 templates with various termini. The last 4-nt sequences of DNA templates are indicated
20 on top of the gel. **(E)** Quantification of the full-length dsRNA shown in **(D)**. The gray
21 values of the gel bands corresponding to the run-off ssRNA and the full-length dsRNA
22 were measured, and the percentage of full-length dsRNA was calculated as the ratio
23 between the full-length dsRNA and the sum of the run-off ssRNA and the full-length
24 dsRNA. **(F)** Agarose gel electrophoresis analysis of the IVT products of T7 RNAP on
25 DNA templates with various termini. The original DNA template ends with four Ts.
26 Each of these four Ts was substituted with A, G, or C, and the production of full-length
27 dsRNA on these templates was analyzed. **(G)** Dot blot analysis of transcripts shown in
28 **(F)**, demonstrating their full-length dsRNA contents. **(H)** Quantification of the full-
29 length dsRNA shown in **(G)**. dsRNA content was normalized to that obtained using the

1 original DNA template (four Ts). DNA templates, ssRNA, and dsRNA are indicated by
2 blue, green, and orange arrows, respectively, in all gels.

3

4 **Figure 3.** Representative ssRNAPs and their production of full-length dsRNA in IVT.

5 **(A)** Schematic showing *Autographivirinae* clusters based on genome sequence
6 comparison (an inaccurately modified version of Fig. 3 in (38)). **(B)** Schematic
7 illustration of the genome organization of phage T7, SP6, Syn5, KP34, and VSW-3.
8 The approximate positions of T7, SP6, and Syn5 promoters are indicated by downward
9 arrows. Genome sizes are also shown. **(C)** Agarose gel electrophoresis analysis of the
10 GFP transcripts synthesized by representative ssRNAPs in IVT. **(D)** Quantification of
11 the results shown in **(C)**. The gray values of the gel bands corresponding to the run-off
12 ssRNA and the full-length dsRNA were measured, and the percentage of the full-length
13 dsRNA was calculated as the ratio between the full-length dsRNA and the sum of the
14 run-off ssRNA and the full-length dsRNA. Gel bands corresponding to ssRNA and
15 dsRNA are indicated by green and orange arrows, respectively.

16

17 **Figure 4.** C-helix mutations in T7 RNAP affect the production of full-length dsRNA.

18 **(A)** Structures of the C-helix in the T7 RNAP initiation complex (IC, PDB: 2PI4) and
19 elongation complex (EC, PDB: 1MSW). Residue G47 is colored in red, and S43 is
20 colored in purple. **(B)** Agarose gel electrophoresis analysis of GFP transcripts
21 synthesized by wild-type T7 RNAP and its mutants E42Y, S43Y, E45Y, M46Y, G47Y,
22 and E48Y in IVT. **(C)** Quantification of the results shown in **(B)**. The gray values of
23 the gel bands corresponding to the run-off ssRNA and the full-length dsRNA were
24 measured, and the percentage of the full-length dsRNA was calculated as the ratio
25 between the full-length dsRNA and the sum of the run-off ssRNA and the full-length
26 dsRNA. **(D)** Agarose gel electrophoresis analysis of GFP transcripts synthesized by
27 wild-type T7 RNAP and its mutants G47F, G47W, G47Y, G47H, and G47A in IVT.
28 **(E)** Dot blot analysis of dsRNA contents from samples in **(D)**. **(F)** Quantification of the
29 full-length dsRNA shown in **(E)**. dsRNA content was normalized to that obtained using

1 wild-type T7 RNAP. Gel bands corresponding to ssRNA and dsRNA are indicated by
2 green and orange arrows, respectively.

3

4 **Figure 5.** C-helix mutations affect the DNA binding by T7 RNAP. **(A)** Agarose gel
5 electrophoresis analysis of GFP transcripts synthesized by wild-type T7 RNAP and its
6 mutants E42K, E45K, and E48K. **(B)** Dot blot analysis of dsRNA contents from
7 samples in **(A)**. **(C)** Quantification of the full-length dsRNA shown in **(B)**. dsRNA
8 content was normalized to that obtained using wild-type T7 RNAP. **(D)** Binding of
9 wild-type T7 RNAP or its G47W or E45K mutant to a 40-bp DNA sequence without
10 T7 promoter. The incubated complexes were analyzed by 12% native PAGE, and the
11 bands corresponding to unbound DNA and the DNA–RNAP complex are marked. **(E)**
12 Quantification of the results shown in **(D)**. The gray values of the gel bands
13 corresponding to the unbound and bound DNA were measured, and the percentage of
14 bound DNA was calculated as the ratio between the bound DNA and the sum of the
15 bound and unbound DNA. **(F)** Binding of wild-type T7 RNAP or its G47W or E45K
16 mutant to a 57-bp DNA sequence with a T7 promoter. The incubated complexes were
17 analyzed by 10% native PAGE, and the bands corresponding to unbound DNA and the
18 DNA–RNAP complex are marked. **(G)** Quantification of the results shown in **(F)**. **(H)**
19 20% denaturing PAGE analysis of the IVT transcripts from wild-type T7 RNAP or its
20 G47W or E45K mutant at the indicated time points. IVT reactions were initiated by the
21 fluorescently labeled dinucleotide 6-FAM-GG, and results were visualized by
22 fluorescence imaging. The run-off RNA, abortive RNA, and unincorporated 6-FAM-
23 GG are marked. **(I)** Quantification of the run-off RNA shown in **(H)**. The gray values
24 of the gel bands corresponding to the run-off RNA and the abortive RNA were
25 measured. Run-off RNA yield was normalized to that obtained using wild-type T7
26 RNAP in the left panel. The percentage of abortive RNA was calculated as the ratio
27 between abortive RNA and the sum of the abortive RNA and the run-off RNA. The
28 percentage of abortive RNA was normalized to the percentage obtained using wild-type
29 T7 RNAP in the right panel. The abortive RNA obtained using the E45K mutant was

1 undetectable. Gel bands corresponding to ssRNA and dsRNA are indicated by green
2 and orange arrows, respectively.

3

4 **Figure 6.** T7 RNAP-G47W is advantageous for mRNA synthesis. **(A)** 1.5% agarose
5 gel electrophoresis analysis of the IVT production of GFP RNA by T7 RNAP (WT) or
6 its G47W or G47A+884G mutant. **(B)** Quantification of the run-off ssRNA shown in
7 **(A)**. The gray values of the gel bands corresponding to the run-off ssRNA were
8 measured. The run-off ssRNA yield was normalized to that obtained using wild-type
9 T7 RNAP. **(C)** 1.5% agarose gel electrophoresis analysis of the IVT production of Cas9
10 RNA by T7 RNAP (WT) or its G47W or G47A+884G mutant. **(D)** Quantification of
11 the run-off ssRNA shown in **(C)**. **(E)** 1.5% agarose gel electrophoresis analysis of the
12 IVT production of S-gene RNA by T7 RNAP (WT) or its G47W or G47A+884G
13 mutant. **(F)** Quantification of the run-off ssRNA shown in **(E)**. DNase I treatment was
14 omitted for all reactions shown in panels **(A)**, **(C)**, **and (E)**, and the DNA template is
15 shown as a loading control. DNA templates, ssRNA, dsRNA, and terminated RNA are
16 indicated by blue, green, orange, and purple arrows, respectively, in panels **(A)**, **(C)**,
17 **and (E)**. **(G)** Expression levels of GFP mRNA produced by T7 RNAP-WT or T7
18 RNAP-G47W in 293T cells recorded by fluorescence microscopy at 4, 16, and 20 h
19 after transfection. **(H)** Fluorescence intensity of cells transfected with GFP mRNA
20 synthesized by T7 RNAP-WT or T7 RNAP-G47W at 20 h after transfection, as
21 determined by flow cytometry. **(I)** Concentrations of IFN- β in cells transfected with
22 GFP mRNA synthesized by T7 RNAP-WT or T7 RNAP-G47W at 20 h after
23 transfection. The cells treated with lipofectamine2000 alone served as the control.

24




Figure 1




Figure 2




Figure 3




Figure 4




Figure 5




Figure 6